- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00902434
Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era
Retrospective Analysis of Histologies, Pattern of Care, and Outcomes of Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era: A Report From the Chicago Lymphoma Consortium
This is an exploratory analysis that is investigating the pattern of care in patients over the age of 80 who were diagnosed with non-Hodgkin lymphoma (NHL). This study will look at the dose intensity and density implemented in this patient population to calculate whether patients received the full course of therapy, received less duration of treatment, or received lower doses of the drugs administered. Furthermore, the investigators would explore time to disease progression for these patients regardless of the treatment received and investigate whether patient outcomes differ based on the type of therapy or dose intensity/density given.
This study is looking at retrospectively evaluating patients with NHL who are over the age of 80 at our institution between 2001-2007. It is anticipated that about 50 patients will be included in this study.
연구 개요
상태
정황
상세 설명
Non-Hodgkin Lymphoma (NHL) is a malignant disease of the lymphoid and hematopoetic system with an annual incidence of 60,000 cases/year in the United States accounting for over 18,000 deaths annually. NHL is a heterogeneous malignancy with a median age of 65 at the time of diagnosis. Most clinical trials that have established current standards of care did not include elderly patients, especially those who are above the age of 80. Reasons for such under representation are not well-defined but several factors are hypothesized. Patients above the age of 80 have many co-morbid conditions that might exclude them from enrollment on clinical studies that are usually designed for more fit individuals. In addition, investigators are often reluctant to propose trials to elderly patients as their response to therapy might be suboptimal compared with younger patients affecting the overall data.
Well-designed published studies as to how patients over the age of 80 are being managed in the community or academic setting are lacking. There is no agreed-upon treatment algorithm for these patients and recommended approach varies based on the treating physician, the institution, and each individual patient.
Some physicians chose to offer dose reductions while others might omit chemotherapy and use monoclonal antibodies alone. Furthermore, treatment duration and the number of cycles given might vary considerably in this patient subgroup for a variety of reasons, mainly toxicity. In addition, it is unclear whether the histologic distribution of NHL is similar in older patients. In other words, it is not clear whether patients over the age of 80 are commonly diagnosed with diffuse large cell lymphoma (DLCL) and follicular lymphoma (FL) similar to younger individuals. Most importantly, these expected variations in treatment strategies might have inferior outcomes when compared to younger patient population. Looking at histologic subtype, treatment strategies, and outcomes in patients over the age of 80 is useful for patients and physicians alike. It is plausible that our current standards do not apply to this very-older patient population arguing for offering them clinical trials or novel agents even as an initial approach. On the other hand, we might discover that these older patients fare well despite these variations arguing that their disease biology is different especially if we note changes in histologic distribution.
연구 유형
등록 (실제)
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Patients with any NHL diagnosis regardless of histology who are over the age of 80 at the time of diagnosis will be included and analyzed.
- Data on age, gender, performance status, and major co-morbid conditions will be collected.
- Histology of the diagnosed NHL will be recorded. The grade (1, 2, or 3) for those who were diagnosed with follicular lymphoma will also be recorded.
- Stage of the disease, presence of bulky nodes and B symptoms will also be recorded.
- PET scan results if available.
- Type of treatment received will be recorded.
- Responses to therapy.
- Outcomes of treatment implemented and toxicities incurred.
- Subsequent therapies if applicable.
Exclusion Criteria:
- None. All charts of patients who are above the age of 80 at the time of NHL diagnosis will be analyzed.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
비호지킨 림프종에 대한 임상 시험
-
Henan Cancer HospitalFundamenta Therapeutics, Ltd.아직 모집하지 않음Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited중국
-
Wael Elbanna ClinicFetal Medicine Research Center, Spain모병임신 여성: 1- ICSI-PGS 2- ICSI-non-PGS 3- 자연 임신 여성이집트
-
UPECLIN HC FM Botucatu Unesp완전한
-
UPECLIN HC FM Botucatu Unesp완전한
-
Fundacion para la Investigacion Biomedica del Hospital...Fundación Mutua Madrileña완전한간세포 암 | 후천면역결핍증후군 바이러스 | 간염, 바이러스, Non-A, Non-B, 비경구적으로 전염됨스페인
-
UPECLIN HC FM Botucatu Unesp알려지지 않은HIV 감염 | 후천성 면역 결핍 증후군 | 간염, 바이러스, Non-A, Non-B, 비경구적으로 전염됨브라질
-
Fundamenta Therapeutics, Ltd.The First Affiliated Hospital of Zhengzhou University아직 모집하지 않음Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
-
Holostem Terapie Avanzate s.r.l.IRCCS San Raffaele; University of Modena and Reggio Emilia모병Junctional Epidermolysis Bullosa Non-Herlitz Type프랑스, 이탈리아
-
Millennium Pharmaceuticals, Inc.완전한GCB(Non-Germinal B-cell-like) 미만성 거대 B-세포 림프종(DLBCL)미국